Active, not recruitingPhase 1NCT04201873

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jonsson Comprehensive Cancer Center
Principal Investigator
Timothy F Cloughesy
UCLA / Jonsson Comprehensive Cancer Center
Intervention
Dendritic Cell Tumor Cell Lysate Vaccine(biological)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
20202027

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Phase One Foundation · Oncovir, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04201873 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials